Q1 FY2025 · Presentation
2025-06-26 Pemvidutide Phase 2b IMPACT Topline Results FINAL · 23 pages
Read Altimmune, Inc.'s results firsthand
Preview the first 2 pages of this presentation
Create a free account to start reading
Full documents are included with Professional
